Research programme: cancer therapeutics - Genexine

Drug Profile

Research programme: cancer therapeutics - Genexine

Alternative Names: GX-02; GX-06

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator Genexine
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Cervical cancer; Haematological malignancies; Head and neck cancer; Skin cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Dec 2015 Preclinical trials in Head and neck cancer in South Korea (unspecified route) prior to December 2015
  • 04 Dec 2015 Preclinical trials in Haematological malignancies in South Korea (unspecified route) prior to December 2015
  • 04 Dec 2015 Preclinical trials in Cervical cancer in South Korea (unspecified route) prior to December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top